Picture of Fresenius Medical Care AG logo

FME — Fresenius Medical Care AG News Story

0.000.00%
de flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

Germany's Fresenius Medical Q4 revenue beats analyst expectations

Overview

Germany dialysis provider's Q4 revenue beat analyst expectations

Operating income for FY 2025 reached the upper end of financial outlook

Company announced EUR 1 bln share buyback program

Outlook

Fresenius Medical expects 2026 revenue growth to be broadly flat compared to prior year

Company forecasts 2026 operating income growth between positive and negative mid-single digits

Fresenius Medical aims for 3-7% CAGR operating income growth from 2025 to 2028

Result Drivers

EFFICIENCY GAINS - Fresenius Medical Care attributed its profitability increase to efficiency gains from the FME25+ program and favorable reimbursement developments

PORTFOLIO OPTIMIZATION - Divestitures as part of the portfolio optimization plan negatively impacted revenue by EUR 244 mln in 2025

SHARE BUYBACK - Accelerated share buyback program supported EPS growth

Company press release: ID:nPn2FVZ3ka

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueBeatEUR 5.07 blnEUR 4.84 bln (7 Analysts)
Q4 Net IncomeEUR 327 mln
Q4 Basic EPSEUR 1.14
Q4 EBITEUR 594 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy", 8 "hold" and 7 "sell" or "strong sell" The average consensus recommendation for the healthcare facilities & services peer group is "buy." Wall Street's median 12-month price target for Fresenius Medical Care AG is €47.00, about 13.6% above its February 23 closing price of €41.39 The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Fresenius Medical Care AG

See all news